MYBL2 is upregulated in many cancers, such as breast cancer, hepatocellular carcinoma, lung cancer, and colorectal cancer, and upregulated expression of MYBL2 is associated with poor prognosis in patients with cancer. This evidence concerns the gene MYBL2 and breast carcinoma.